Optimind Pharma Closes First Tranche of Private Placement
Summary
All securities issued in connection with the private placement are subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.Optimind Pharma is an emerging provider of psychedelic therapies. From specializing in prescribing medical cannabis, ketamine-assisted treatment, and other psychedelic-enhanced psychotherapy modalities, Optimind Pharma helps individuals suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities.Optimind exists to combine the power of psychedelic medicine with the science of psychology to provide legal psychedelic enhanced psychotherapy in a safe, controlled environment.To learn more about Optimind Pharma, visit https://optimindpharma.com/.This news release contains forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. There are numerous risks and uncertainties that could cause actual results and the Companys plans and objectives to differ materially from those expressed in the forward-looking information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITYFOR THE ADEQUACYOR ACCURACYOF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215811